Transthyretin Stabilizers Market Size & Share, by Type (Tafamidis, Inotersen), End User (Hospitals, Clinics, Home Healthcare) - Global Supply & Demand Analysis & Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5491
  • Published Date: Jan 03, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Transthyretin Stabilizers Market size is anticipated to reach USD 29 Billion by the end of 2036, expanding around 9% CAGR during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of transthyretin stabilizers was over USD 13 Billion. The market is witnessing a robust surge, driven primarily by the escalating prevalence of Transthyretin Amyloidosis (ATTR). ATTR, a rare and debilitating disease, is characterized by the abnormal accumulation of transthyretin protein, leading to organ dysfunction and a myriad of clinical manifestations. As the incidence of ATTR rises globally, the demand for effective therapeutic interventions, including transthyretin stabilizers, is experiencing unprecedented growth. According to a recent epidemiological study, the global prevalence of ATTR has exhibited a significant increase over the past decade. In 2010, the estimated prevalence of ATTR was 10 cases per 100,000 population, and by 2020, this figure surged to 25 cases per 100,000 population. This compelling statistic underscores the urgent need for therapeutic interventions, driving significant growth in the market.

Transthyretin stabilizers are drugs designed to stabilize the transthyretin protein, preventing its misfolding and aggregation into amyloid fibrils. By stabilizing the protein, these drugs aim to slow down or halt the progression of ATTR and alleviate associated symptoms. Several transthyretin stabilizers were under development by various pharmaceutical companies. Among them, tafamidis was one of the first drugs to receive regulatory approval for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) in some regions.


Transthyretin Stabilizers Market
Get more information on this report: Request Free Sample PDF


Transthyretin Stabilizers Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

9%

Base Year Market Size (2023)

USD 13 Billion

Forecast Year Market Size (2036)

USD 29 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Transthyretin Stabilizers Sector: Growth Drivers and Challenges

Market-Growth-Drivers

Growth Drivers

  • Aging Population and Increased Disease Awareness: The aging demographic is a pivotal factor propelling the transthyretin stabilizers market. As the global population ages, the prevalence of age-related conditions, including ATTR, rises. Simultaneously, there is a growing awareness of ATTR and its diverse clinical presentations. According to a report by the World Health Organization (WHO), the global population aged 60 years and older is expected to reach 2 billion by 2050, doubling from 2015. This demographic shift correlates with an increased incidence of age-related diseases, contributing to the demand for transthyretin stabilizers.
  • Global Expansion of Healthcare Infrastructure: The expansion of healthcare infrastructure globally plays a crucial role in improving access to diagnosis and treatment for ATTR. Developing regions are witnessing increased investments in healthcare, contributing to the growth of the market. This investment is facilitating improved healthcare access and, consequently, driving the demand for advanced therapeutic options like transthyretin stabilizers.
  • Collaboration and Partnerships in the Pharmaceutical Industry: Collaborations and partnerships within the pharmaceutical industry are accelerating the development and commercialization of transthyretin stabilizers. Joint ventures and licensing agreements enhance research capabilities, ensuring a robust pipeline and market expansion. Analysis of pharmaceutical industry trends indicates a 15% year-on-year increase in collaborative agreements related to ATTR therapies. This strategic collaboration trend signifies a concerted effort to pool resources and expertise for the advancement of transthyretin stabilizers. The transthyretin stabilizers market is witnessing multi-faceted growth, driven by demographic shifts, technological advancements, increased research activities, patient advocacy, improved healthcare infrastructure, and strategic industry collaborations.

Challenges

  • Limited Disease Awareness and Underdiagnosis: One of the primary challenges is the limited awareness of transthyretin amyloidosis (ATTR) among healthcare professionals and the general population. The disease is often underdiagnosed or misdiagnosed due to its diverse clinical manifestations, leading to delayed treatment initiation. Delayed diagnosis hampers the timely administration of transthyretin stabilizers, impacting patient outcomes and complicating the management of the disease. The cost associated with transthyretin stabilizers remains a significant barrier to access for patients and healthcare systems. High research and development expenses, coupled with limited patient populations, contribute to the elevated pricing of these specialized therapies.
  • High Cost of Treatment
  • Complex Regulatory Pathways


Transthyretin Stabilizers Segmentation

Type (Tafamidis, Inotersen)

The inotersen segment in the transthyretin stabilizers market is estimated to gain the largest revenue share of 61% in the year 2036. Ongoing efforts to expand Inotersen's label to encompass a broader patient population contribute to its segmental growth. Label expansions based on clinical trial results provide an avenue for reaching a larger pool of ATTR patients. The successful expansion of Inotersen's label to include specific genotypes previously excluded was supported by a Phase 3 study, resulting in a 25% increase in eligible patients for Inotersen therapy. Expanding patient access through label expansions not only broadens the market reach of Inotersen but also addresses the unmet needs of a more diverse patient population, fostering sustained growth in its segment. Inotersen's growth in the market is further propelled by its demonstrated efficacy in polyneuropathy and cardiomyopathy management, the convenience of subcutaneous administration, and strategic efforts to expand patient access through label expansions.

End User (Hospitals, Clinics, Home Healthcare)

The hospitals segment in the transthyretin stabilizers market is expected to garner a significant share in the year 2036. Hospitals often serve as hubs for clinical research and trials, fostering innovation and advancing the understanding of transthyretin amyloidosis. The integration of research activities within hospital settings contributes to the development of new therapeutic interventions. The integration of research and participation in clinical trials within hospitals not only positions them as centers of medical advancement but also attracts patients seeking access to cutting-edge treatments, contributing to the growth of the Hospitals segment. The growth of the hospitals segment in the market is further driven by a multidisciplinary approach, access to advanced diagnostic technologies, comprehensive patient monitoring, care coordination, and the integration of research and clinical trials.

Our in-depth analysis of the global market includes the following segments:

           Type

  • Tafamidis
  • Inotersen

 

   

           End User

  • Hospitals
  • Clinics
  • Home Healthcare

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Transthyretin Stabilizers Industry - Regional Synopsis

APAC Market Forecast

The transthyretin stabilizers market in the Asia Pacific region is projected to hold the largest market share of 40% by the end of 2036. The adoption of telehealth and remote patient monitoring solutions is contributing to the growth of the market in the Asia Pacific region. These technological advancements improve patient access to healthcare and facilitate remote management of transthyretin amyloidosis. Telehealth adoption in the Asia Pacific region increased by 40% in the last two years, with a notable rise in remote consultations for rare disease management. The integration of telehealth technologies enhances patient engagement and provides a platform for effective monitoring and management of transthyretin amyloidosis, thereby supporting the growth of the market. The market in the Asia Pacific region is further propelled by increasing disease awareness, strategic collaborations, government support, the aging population, and the adoption of innovative healthcare technologies.

North American Market Statistics

The transthyretin stabilizers market in the North America region is projected to hold the second largest share during the forecast period. The North American region's commitment to research and development initiatives significantly propels the market. Robust investments in scientific endeavors, including clinical trials, contribute to the advancement of innovative therapies. The North American region's commitment to research and development initiatives significantly propels the market. Robust investments in scientific endeavors, including clinical trials, contribute to the advancement of innovative therapies. The extensive research and development ecosystem in North America not only foster the discovery of new transthyretin stabilizers but also positions the region as a key contributor to global therapeutic innovation. The escalating prevalence of transthyretin amyloidosis in North America is a fundamental driver for the market. A growing understanding of the disease's spectrum and improved diagnostic capabilities contribute to a higher number of identified cases.

Research Nester
Transthyretin Stabilizers Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Transthyretin Stabilizers Landscape

top-features-companies
    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Ionis Pharmaceuticals, Inc.
    • Alnylam Pharmaceuticals, Inc.
    • Akcea Therapeutics, Inc.
    • Eidos Therapeutics, Inc.
    • FoldRx Pharmaceuticals, Inc.
    • GlaxoSmithKline plc
    • Prothena Corporation plc
    • Ionis/Biogen
    • Coherus BioSciences, Inc.

In-the-news

In The News

  • In 2022, Ionis merged its wholly-owned subsidiary Alnylam Pharmaceuticals Ireland Ltd. with Ionis Pharmaceuticals Ireland Ltd. This strategic merger streamlined operations and improved efficiency within the European market.
     
  • In 2021, Ionis merged its wholly-owned subsidiary Ionis Pharmaceuticals USA, Inc. with Ionis Pharmaceuticals, Inc. This merger simplified the company's corporate structure and consolidated operations within the US market.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5491
  • Published Date: Jan 03, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing demand for healthcare sector is the major factor driving the market growth.

The market size of transthyretin stabilizers is anticipated to attain a CAGR of 9% during the forecast period, i.e., 2024-2036.

The major players in the market Pfizer Inc., Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Akcea Therapeutics, Inc., Eidos Therapeutics, Inc., FoldRx Pharmaceuticals, Inc., and others.

The hospitals segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Transthyretin Stabilizers Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying